BAK1 and neoplasm: While it has previously been reported that BAK levels are low in normal postnatal cells and higher in tumor cells [53], providing a potential opportunity for selective tumor cell killing using a BAK direct activator, it is possible that such an activator will be even more selective if administered as a payload attached to an antibody that selectively binds to certain tumor cells.